Search

Displaying results 3451 - 3460 of 10000 in total
  1. Drug

    Clevidipine

    go.drugbank.com/drugs/DB04920
    ApprovedInvestigational

    Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: Cleviprex 0,5 mg/ml Emulsion zur Injektion
  2. Drug

    Ramelteon

    go.drugbank.com/drugs/DB00980
    ApprovedInvestigational

    Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: RAMELDA 8 MG FILM KAPLI TABLET,30 ADET, ROZEREST 8 MG FİLM KAPLI TABLET, 10 ADET
  3. Pathway

    5-Oxoprolinuria

    smpdb.ca/view/SMP0125615
    Disease

    5-Oxoprolinuria (5-Oxoprolinase deficiency) is a result of a defect in the gamma-glutamyl cycle due to either 5-oxoprolinase or glutathione synthetase deficiency. … In the case of 5-oxoprolinase, however, pyroglutamic acid accumulates. Symptoms include anemia, mental retardation, metabolic acidosis, respiratory distress and urolithiasis.

    Drugs: Glutamic acid · Glutathione · Glycine · Cysteine · Alanine · ATP +5 more
    Enzymes: 5-oxoprolinase
  4. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449] … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesProducts: KERENDİA 10 MG FİLM KAPLI TABLET, 98 ADET, KERENDİA 20 MG FİLM KAPLI TABLET, 98 ADET
  5. Drug

    Cholecalciferol

    go.drugbank.com/drugs/DB00169
    ApprovedInvestigationalNutraceutical

    Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight [L5689]. … Appropriate levels of vitamin D must be upheld in the body in order to maintain calcium and phosphorus levels in a healthy physiologic range to sustain a variety of metabolic functions, transcription regulation

    Synonyms: (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol, (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-olInternational brands: Delta-D, Micro-D
  6. Drug

    Adefovir dipivoxil

    go.drugbank.com/drugs/DB00718
    Approved

    of hepatitis B. … It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.

    International brands: A Di Xian, A Gan DingCategories: Heterocyclic Compounds, 2-Ring, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
  7. Pathway

    Acylcarnitine 5-(5-heptyl-3-methylfuran-2-yl)pentanoylcarnitine

    smpdb.ca/view/SMP0123512
    Metabolic

    5-(5-heptyl-3-methylfuran-2-yl)pentanoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, 5-(5-heptyl-3-methylfuran-2-yl)pentanoyl-CoA reacts with L-carnitine to form 5-(5-heptyl-3-methylfuran-2-yl)pentanoylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
    Enzymes: Solute carrier family 22 member 5
  8. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: XTANDI ® 40 MG, XTANDI® 40 MG
  9. Drug

    Pinazepam

    go.drugbank.com/drugs/DB13335
    Investigational

    Categories: Heterocyclic Compounds, 2-RingProducts: DOMAR CAPSULE 5 mg
  10. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell … [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]

    Synonyms: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-oneCategories: MATE 2-K Inhibitors, P-glycoprotein substrates with a Narrow Therapeutic Index